TD Cowen cuts Stryker stock price target on cybersecurity impact By Investing.com

TD Cowen cut Stryker’s price target to $355 from $387 while keeping a Hold rating, citing the impact and uncertain recovery cadence of the recent cybersecurity incident. The company’s Q1 2026 results also missed expectations, with revenue of $6.02B versus $6.35B consensus and EPS of $2.60 versus $2.98, though full-year guidance was maintained. Other firms also reduced targets, but several retained positive ratings, reflecting a mixed outlook.

Analysis

SYK’s reset is less about one bad quarter and more about a confidence shock to a premium multiple that depended on smooth execution and hospital capital spending visibility. When a med-tech platform misses on both revenue and EPS after a disruption, the market typically de-risks the entire franchise, not just the quarter, because procurement teams and investors start baking in a slower normalization curve and more conservative order timing. That creates a window where fundamentals can look worse than the eventual cash earnings power, but only if the company regains operating tempo quickly.

The second-order winners are the companies that can fill product gaps or win delayed capital budgets while SYK works through backlogs. In med-tech, that usually benefits larger diversified peers with cleaner execution and stronger service footprints, since hospitals will shift spend toward suppliers that can deliver reliably; the near-term beneficiary is less about category share and more about purchasing confidence. The real loser is the valuation framework itself: if double-digit growth is no longer a credible baseline, the stock can de-rate another turn or two even without additional fundamental deterioration.

The key catalyst set is operational, not macro: restoration of manufacturing throughput, order fulfillment, and evidence that the cyber event did not permanently impair customer relationships over the next 1–3 quarters. If management can show sequential margin repair and a return to normal backlog conversion, the current drawdown becomes a buying opportunity; if not, the market will treat guidance maintenance as a floor, not a sign of strength. In that scenario, the risk is a slow-burn multiple compression rather than a further sharp earnings cut.

The contrarian view is that the selloff may be overdone relative to long-cycle demand durability: elective procedure volumes and hospital capex are sticky, and the stock is already pricing in a meaningful operational reset. The market is also underweighting the possibility that the incident forces a cleaner operating model and tighter supply-chain controls that improve future reliability. But absent proof of recovery, this is still a hold-to-lower case, not a clear dip-buy for event-driven capital.

Key Decisions for Investors

• Short SYK for 1-3 months against the view that post-incident recovery will be linear; use a tight stop above the post-event consolidation high, targeting another 5-8% downside if fulfillment remains uneven.
• Pair trade: long a cleaner-execution diversified med-tech peer basket vs short SYK for 2 quarters; the thesis is relative multiple compression in the name with the most visible operational scar.
• Sell upside calls on SYK into any relief rally over the next 2-4 weeks; implied volatility should stay bid until management shows two consecutive prints of normalizing orders and margins.
• If you want long exposure, wait for confirmation in the next earnings cycle rather than averaging now; the better entry is after evidence of backlog conversion, where risk/reward improves materially.
• Monitor hospital-capex-sensitive suppliers for share capture over the next 1-2 quarters; any acceleration there strengthens the short-SYK relative-value case.